Success Story: A Clinical Research Scientist Got an NIW Success Without Receiving Any RFE

Client’s Testimonial:

“Thanks a million to your wonderful team for the great job done, really appreciate it!”

On September 18^th, 2025, we received another EB-2 NIW (National Interest Waiver) approval for a Clinical Research Scientist in the Field of Biotechnologies (Approval Notice).

General Field: Biotechnologies

Position at the Time of Case Filing: Clinical Research Scientist

Approval Notice Date: September 18^th, 2025

Processing Time: 20 months, 2 days

Case Summary:

NAILG successfully secured NIW approval for a biotechnology researcher specializing in clinical trial methodologies. His work centers on developing innovative approaches to evaluate new treatments, vaccines, and medical devices, with the ultimate goal of improving patient diagnosis and optimizing health outcomes.

Research with Substantial Merit and National Importance

The client’s research directly advances both biotechnology innovation and public health. By designing novel clinical trial methodologies, he helps ensure that medical devices and emerging vaccines are tested efficiently and effectively. This work reduces the time and cost of drug development while accelerating access to life-saving therapies – a crucial priority in a healthcare system where costs are rising and timely innovation is essential. His studies on hemoglobin measurement in resource-limited settings, antibiotic resistance in urinary tract infections, and malaria vaccine efficacy have provided practical insights with global health applications.

Evidence of Accomplishments

To support the petition, NAILG highlighted the client’s strong academic and professional record, including:

8 peer-reviewed journal articles published in respected journals in the field of biotechnology.
295 citations to his work, demonstrating recognition and reliance on his findings by independent researchers worldwide.
Peer review service for scientific journals, with at least 2 reviews completed, reflecting his standing as a trusted evaluator of cutting-edge research.
Major funding support from GlaxoSmithKline (GSK), further underscoring the importance of his contributions to vaccine and medical research.

Additionally, the petition included 4 letters of recommendation from leading experts in the field, attesting to his influence and future promise.

“[Client’s] skillset and priceless contributions have placed him on the frontlines of vital vaccine research, and his ongoing successes are certain to benefit the United States’ public health, biomedical, and pharmaceutical industries.”

NIW Approval and Outlook

This NIW approval recognizes both the substantial merit of the client’s research and its direct national importance to the United States. With NAILG’s guidance, the petition clearly demonstrated how his pioneering work in clinical trial methodologies advances biotechnology, strengthens healthcare delivery, and reduces the burden of disease. He is now well-positioned to continue developing innovative approaches that improve treatment evaluation and patient care, contributing to a more efficient and resilient U.S. healthcare system.

--------------------------------------------

North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Ten Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With more than 58,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Hundreds and Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our cumulative total of approved cases grew from 600 in 2013 to over 58,000 in 2025.